Danaher Floating off Environmental & Applied Solutions Segment Enhances Opportunity

Life sciences and diagnostics company Danaher is moving focus on the growth opportunities for Life Sciences and Diagnostics segments. The company intends to float off its Environmental & Applied Solutions (EAS) segment into a separate publicly traded company. DHR would then be to further capitalize on the seen powerful growth in the other segments having been entrenched in the development of COVID-19 vaccines and therapeutics through its $21.4 bln acquisition of Cytiva in 2020. Cepheid also received Emergency Use Authorization … Continue reading “Danaher Floating off Environmental & Applied Solutions Segment Enhances Opportunity”

Danaher The Quiet Achiever With COVID-19 Vaccines and Therapeutics

Danaher is a name not often linked to the Coronavirus vaccine industry. In fact, DHR has been entrenched in the development of COVID-19 vaccines and therapeutics through its $21.4 billion acquisition of Cytiva last March and raised its Q1 guidance to the high end.  Image: Danaher Cytiva Lab Danaher is forecasting core revenue growth to be above the high-end of its previous guidance range as the life sciences and medical diagnostic tools and instruments it manufactures continue to receive order way above … Continue reading “Danaher The Quiet Achiever With COVID-19 Vaccines and Therapeutics”